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Human endogenous retroviruses (ERV) are an integral part of our genome. Expression of
ERV is usually switched off but reactivation of ERV has been observed in varying human
diseases including cancer. Recently, reactivation of ERV associated promoters in Hodgkin’s
lymphoma (HL) cells has been described. Despite relatively good prognosis, not all patients
with HL can be cured with the established therapy and this therapy is associated with
severe late side effects.Therefore, new targets are required for the development of future
treatment strategies. Reactivated ERV might represent such target structures. Therefore,
we asked which ERV loci are expressed in HL cells. Using DNA microarray analysis, we
found no evidence for a general activation of ERV transcription in HL cells. In contrast, we
observed down-regulation of ERV3, an ERV with potential tumor suppressor function, in
HL cells in comparison to normal blood cells. Interestingly, ERV3 was also differentially
expressed in published DNA microarray data from resting versus cycling B cells. Treat-
ment of HL cells with the histone deacetylase inhibitor vorinostat strongly up-regulated
ERV3 expression. In addition, we observed up-regulation in HL cells after treatment with
hypoxia-mimetic cobalt(II) chloride. Like vorinostat, cobalt(II) chloride inhibited cell growth
of HL cells. Our results suggest that cell cycle inhibition of HL cells is accompanied by
up-regulation of ERV3.
Keywords: Hodgkin’s lymphoma, gene expression, endogenous retrovirus ERV3, histone deacetylase inhibitor,
hypoxia-mimetic cobalt(II) chloride
INTRODUCTION
The exact etiology of Hodgkin’s lymphoma (HL) is unknown, but
immunological and molecular properties suggest that the majority
of HL are derived from B cells (1, 2). HL cells have a characteristic
gene-expression profile that discriminates these cells from other
normal and transformed cells (3, 4). Especially for pediatric HL
patients the prognosis is relatively good, and with the combina-
tion of radio- and chemo-therapy the majority of patients with HL
can be cured. However, the established therapy is associated with a
plethora of late adverse side effects and some patients with chemo-
resistant disease cannot be cured (5, 6). Therefore, it is important
to search for new targets for treatment of patients with HL.
Recently, reactivation of endogenous retrovirus (ERV) activity
has been observed in HL (7). This reactivation leads to expres-
sion of the receptor for macrophage colony-stimulating factor
(colony-stimulating factor 1 receptor, CSF1R), a known oncogene,
in HL cells. ERV are an integral part of the genome of virtually
all eukaryotes, and ERV loci have been extensively analyzed in
plants, insects, and vertebrates (8–13). In the human genome,
ERV derived sequences constitute at least 8% of the complete
DNA. Usually, ERV are silenced epigenetically and are not tran-
scribed into RNA. Reactivation of ERV has been observed under
pathological conditions, e.g., in cancer cells. Such reactivation can
result even in the formation of virus particles (14, 15). A small
number of ERV-encoded proteins can be found under normal
physiological conditions. Such proteins can exert variable biolog-
ical functions (16, 17). One notable example is ERVW-1 (also
known as syncytin 1) which is required for proper formation of the
syncytial layer of the placenta (16). In this ERV only the envelope
protein is functional. Other open reading frames (ORF) have been
inactivated by deleterious mutations. Such mutations destroy the
ORF of the majority of ERV. Some ERV with intact ORF encode
superantigens (18, 19). Such superantigens can activate a high
percentage of all T cells. The activation of these T cells can lead
to hyper-reactivity of the immune system but can also lead to the
final deletion of the activated T cells.
In addition to the potential involvement in the pathogenesis of
human diseases, ERV might also represent interesting target struc-
tures for the development of future treatment strategies. Immune
responses against ERV-encoded antigens have been described in
cancer patients (20, 21). In melanoma patients, antibodies against
ERV are associated with shorter disease free survival (21). On the
other hand, cytotoxic T cells with specificity for ERV-encoded anti-
gens can kill melanoma cells (22), colorectal cancer cells (23), and
renal cancer cells (24). In addition, antibodies against ERV prod-
ucts can inhibit growth of breast cancer cells in vitro and in an
animal model (25). Successful immunization of rhesus macaques
against simian ERV suggests that ERV derived antigens can be
used as safe vaccines without development of auto-immunity
(26). Interestingly, ERV-specific T cells have been detected in
patients after allogeneic hematopoietic stem cell transplantation
(alloHSCT) (24). These T cells can kill the tumor cells and might
be responsible for graft-versus-tumor effects after alloHSCT (24).
Graft-versus-tumor effects have also been described in HL patients
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after alloHSCT (27). It remains unclear whether ERV reactivation
in HL cells (7) has an impact on such graft-versus-tumor effects.
We asked whether ERV reactivation in HL is a phenomenon affect-
ing multiple (or all) ERV loci or whether this reactivation is specific
for single ERV loci. Therefore, we used DNA microarray data for
the analysis of multiple ERV loci in HL cells. DNA microarrays
can be used for the characterization of complete gene-expression
profiles from normal and malignant cells in a single experiment
(28). Modern DNA exon microarrays contain several probe sets
with specificity for ERV and, therefore, can be used for analysis of
expression of multiple ERV loci at once.
MATERIALS AND METHODS
CELL LINES AND CELL CULTURE
Hodgkin’s lymphoma-cell lines HDLM-2, KM-H2, L-1236, L-428,
and L-540 (29–33) were obtained from the Deutsche Sammlung
von Mikroorganismen und Zellkulturen (DSMZ), Braunschweig,
Germany. P439-6 cells were kindly provided by G. W. Bornkamm
and G. Laux, Munich, Germany. P493-6 cells carry an EBV nuclear
antigen 2 (EBNA2)-estrogen receptor fusion gene and MYC under
control of a promoter which can be regulated by tetracycline (34–
36). All cells were cultured in RPMI-1640 (Invitrogen, Karlsruhe,
Germany) supplemented with 10% fetal calf serum, 100 U/mL
penicillin, and 100µg/mL streptomycin (PAA, Pasching, Ger-
many) at 37°C in a humidified atmosphere at 5% CO2. Treatment
of HL cells with 1µM vorinostat was carried out as described
(37) at a cell density of 1× 106 cells/mL for 24 h. Dimethyl sulfox-
ide (DMSO) was used as control. For simulation of hypoxia, HL
cells were treated for 2 days at a cell density of 1× 106 cells/mL
with 200µM cobalt(II) chloride. P439-6 cells were cultured for
4 days in medium with or without 2µM estradiol and/or 1µg/mL
tetracycline.
GENE-EXPRESSION ANALYSIS
RNA from cell lines were isolated using TriFast reagent (peqlab,
Erlangen, Germany) following manufacturer’s protocol. Two
micrograms of the RNA were transcribed into cDNA and used
as template for polymerase chain reaction (PCR). The follow-
ing primer combinations were used for real-time quantitative
reverse transcription-PCR (qRT-PCR): actin beta (ACTB): 5′-
GGC ATC GTG ATG GAC TCC G-3′, 5′-GCT GGA AGG TGG
ACA GCG A-3′; ERV3: 5′-GGG AGT ATG CGG AAA GTT CA-3′,
5′-CTC CAA GGG ATG AGA ACC AA-3′. Quantitative RT-PCR
was performed using the Go Taq qPCR Master Mix (Promega,
Mannheim, Germany). The reaction was performed with 10µL
Go Taq qPCR Master Mix, 6µL water, 1µL primer combination,
and 2µL cDNA using the following conditions: 94°C, 30 s; 60°C,
30 s; 72°C, 45 s (40 cycles). Determination of gene expression was
performed using the 2−∆∆Ct method (38). Global gene expres-
sion in HL cell lines was analyzed by using Affymetrix Human
Exon 1.0ST arrays (Affymetrix, Santa Clara, USA). In addition
to microarray data from HL cell lines L-540, HDLM-2 and L-
428 (39), microarray data from normal peripheral blood cells
(40), P493-6 cells (41), and normal B cells (42, 43) were used
for comparative analysis. These cel files were down-loaded from
the gene-expression omnibus (GEO) data base. All cel files were
processed together using the robust microarray analysis (RMA)
algorithm with Expression Console 1.1 (Affymetrix). Cel files from
DNA microarrays from HL cell lines have been submitted to the
GEO data base (accession number GSE47686). Signal intensities
from ERV-specific probe sets were visualized with the Genesis
software (44).
RESULTS
ANALYSIS OF ERV EXPRESSION IN DNA MICROARRAY DATA
We analyzed expression of human ERV in DNA microarray data
from HL cell lines HDLM-2, L-428, and L-540 in comparison to
normal blood cells, normal B cells, and the conditionally immor-
talized B cell line P493-6. A total of 169 probe sets with specificity
for ERV sequences were analyzed (Figure 1). Signal intensities
FIGURE 1 | Heat map of ERV-specific probe sets in the investigated
DNA microarray data. Probe sets with specificity for ERV-related
sequences were selected from microarray data from normal blood cells
[GEO data set GSE18838 (40)], normal B cells [GEO data sets GSE14352
and GSE5188 (42, 43)], P493-6 cells [GEO data set GSE32219 (41)], and HL
cell lines. Signal intensities were visualized using the Genesis software
(log2-transformed and mean centered data). The used arrays contain probe
sets for the following ERV: ERV3-1, ERV3-2, ERV9-1, ERV18-1, ERVFC1-1,
ERVFH21-1, ERVFRD-1, ERVFRD-2, ERVH-1, ERVH-4, ERVH-6, ERVH48-1,
ERVI-1, ERVK3-1, ERVK3-2, ERVK-6, ERVK-7, ERVK-9/-4/-19, ERVK11-1,
ERVK13-1, ERVMER34-1, ERVMER61-1, ERVV-1, ERVV-1/-2, ERVW-1, and
ERVW-6.
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(RMA normalized, linear values) above 100 were considered to be
expressed in the corresponding samples. According to this thresh-
old, HDLM-2 cells expressed 13 different ERV (represented by
31 probe sets), L-428 cells expressed 10 ERV (36 probe sets),
and L-540 cells expressed 11 ERV (28 probe sets). In normal
blood cells, 13 ERV were expressed (43 probe sets with mean
signal intensities above the threshold). Interestingly, the eight
ERV that were expressed in all HL cell lines (ERVFC1-1, ERVH-1,
ERVH-4,ERVH48-1,ERVK3-1,ERVK-7,ERVK-9/-4/-19,ERVK13-
1), were also expressed in normal blood cells. In addition, normal
blood cells expressed ERV3-1, ERVK-6, ERVV-1, ERVW-6, and
ERVMER34-1. Isolated B cells expressed 15 ERV (45 probe sets
with mean signal intensities above the threshold). In addition to
all ERV that were found in normal blood, isolated B cells had
high signal intensities for ERV9-1 and ERVK11-1. Additional ERV
were found only in single HL cell lines: L-428 cells expressed
ERVH-6 ; L-540 cells expressed ERVW-1 and ERVK3-2; HDLM-
2 cells expressed ERVFRD-1 and ERVFRD-2. Taken all together,
the number of expressed ERV in HL cell lines did not exceed the
number of ERV expressed in normal blood or isolated B cells.
Probe sets for ERV3-1 and ERVK13-1 showed significantly lower
(p< 0.01) signal intensities in HL cells than in normal blood cells
(Figure 2A). We found no ERV that were significantly up-regulated
in HL cells. Mean signal intensities for ERV3-1 and ERVK13-1 in
isolated B cells were lower than the signals in whole blood. It is
known from the literature that ERV3 is up-regulated in cell cycle
arrested differentiating cells (45). We tested whether ERV3 is also
up-regulated in cell cycle arrested B cells. For this end, we ana-
lyzed DNA microarray data (41) from P493-6 cells that have been
treated with tetracycline. Tetracycline switches off expression of
MYC in this Burkitt lymphoma model cell line leading to cell cycle
arrest (34–36). As shown in Figure 2B, we detected up-regulation
of all probe sets from Figure 2A in arrested P493-6 cells.
VALIDATION OF ERV3 EXPRESSION IN CELL CYCLE ARRESTED B CELLS
To validate the observation of cell cycle dependent regulation of
ERV3 we performed quantitative RT-PCR with P439-6 cells that
had been cultured under different conditions. Cells were grown in
medium (cycling cells) or after addition of tetracycline (arrested
cells). In addition, the same cells were cultured in the presence
of estrogen. Estrogen switches on functional EBNA2 in these cells
and allows the proliferation in the presence of tetracycline. As
shown in Figure 3, incubation of P493-6 cells with tetracycline
resulted in marked up-regulation of ERV3. Switching on the EBV
transformation program by addition of estrogen to tetracycline-
treated P493-6 cells inhibited this up-regulation. Similar results
were obtained with the conditional EBV-immortalized cell line
EREB2-5 (46). This cell line is the parental cell line of P493-6 cells
(without exogenous MYC) and proliferates only in the presence
of estrogen in the culture medium. In this cell line we observed
up-regulation of ERV3 after withdrawal of estrogen (data not
shown).
REGULATION OF ERV3 EXPRESSION IN HL CELL LINES
In our previous work we observed that treatment of HL cells
with the histone deacetylase inhibitor vorinostat induces cell cycle
arrest (37). Therefore, we asked whether this cell cycle arrest is
FIGURE 2 | ERV with significant difference between HL and normal
blood samples. (A) Presented are signal intensities (means and standard
deviations) of the indicated probe sets (ERV3-1: probe sets 303411 and
3053406; ERVK13-1: probe sets 3677096, 3677094, and 3677095) in
normal blood cells [GEO data set GSE18838 (40)], normal B cells [GEO data
sets GSE14352 and GSE5188 (42, 43)], and HL cell lines. (B) Signal
intensities of the same probe sets in P493-6 cells after treatment with
tetracycline (resting cells) or medium without tetracycline [cycling cells; raw
data from GEO data set GSE32219 (41)].
FIGURE 3 | Expression of ERV3 in P439-6 cells. Expression of ERV3 was
analyzed in P439-6 cells under different culture conditions by qRT-PCR.
Cells were cultured in the absence or presence of estrogen (E) and/or
tetracycline (T). Presented are means and standard errors from duplicate
determinations. For comparative analysis, beta actin was used as
housekeeping control and the mean of P439-6 cells cultured in medium
was set as 1.
also accompanied by up-regulation of ERV3 in HL cells. Figure 4
show the results of this analysis. Incubation of all tested HL cell
lines with vorinostat resulted in an increased expression of ERV3.
We observed that treatment of HL cells with the hypoxia-mimetic
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FIGURE 4 | Incubation of HL cells with the histone deacetylase
inhibitor vorinostat leads to increased expression of ERV3 . Expression
of ERV3 was analyzed in HL cell lines with and without 1µM vorinostat by
quantitative RT-PCR. Presented are means and standard errors from
triplicates. Beta actin was used as housekeeping control and the mean of
the HL cells without vorinostat was set as 1.
CoCl2 led to a pronounced inhibition of proliferation (Figure 5).
As shown in Figure 6, the expression of ERV3 again increased when
cells were cultured under conditions of inhibited proliferation.
DISCUSSION
Increased expression of ERV derived sequences has been observed
in cancer cells (14, 15, 47–51) and in patients with autoimmune
diseases or neurodegenerative diseases (52–54). ERV can act as
alternative promoters for adjacent genes (7, 55–58). The result-
ing fusion transcripts can result in new protein isoforms, or the
ERV component of these fusion transcripts can inhibit translation
(58). In addition, ERV expression can interfere with the expres-
sion of adjacent genes at the level of transcription (59). In cancer
cells such interference may lead to the inactivation of tumor sup-
pressor genes. Some ERV-encoded proteins can directly bind and
inactivate tumor suppressor genes (60). In our present study we
provide preliminary evidence for a differential expression of ERV3
in HL cells under conditions of growth arrest. The method used
for analysis of ERV expression in HL has several limitations. Not
all human ERV loci are represented on the arrays and it might
FIGURE 5 | Incubation of HL cells with cobalt(II) chloride inhibits
proliferation. Cells of the indicated cell lines were cultured in the presence
or absence of 200µM cobalt(II) chloride for 4 days. Thereafter the cell
number was determined. Percentage of increase in cell number was
calculated as [(final cell number)/(starting cell number)×100].
FIGURE 6 | Incubation of HL cells with cobalt(II) chloride leads to an
increased expression of ERV3 . Expression of ERV3 was analyzed in HL
cell lines L-428, L-540, KM-H2, and HDLM-2 after treatment with 200µM
cobalt(II) chloride or without cobalt(II) chloride by quantitative RT-PCR. Beta
actin was used as housekeeping control and the mean of HL cells without
cobalt(II) chloride was set as 1.
be that other ERV are differentially expressed in the investigated
cells. In addition, the comparability of our data sets from HL cells
and published data sets from normal blood and B cells might also
be sub-optimal. However, our results gave no evidence for a gen-
eral up-regulation of the investigated ERV loci in HL cells. The
ERV3 signals in normal B cells are relatively low. Therefore and
based on the limitations of the study, we cannot conclude that the
low ERV3 expression is a specific feature of HL cells. However,
up-regulation of ERV3 in HL cells under conditions of growth
arrest suggests that ERV3 might be an interesting gene for fur-
ther studies. ERV3 is unique among ERV as it is considered to
be a tumor suppressor (61). ERV3 is abundantly expressed in the
placenta and it is expressed in most other tissues at lower lev-
els (62). Absence of expression in choriocarcinoma was observed
(62), and transgenic expression of ERV3 in choriocarcinoma cells
inhibits cell proliferation (63). This growth inhibition is associated
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with down-regulation of cyclin B and up-regulation of the cyclin
dependent kinase inhibitor p21 (63). Expression of ERV3 is up-
regulated during terminal differentiation of leukemia cells and
highest in cell cycle arrested cells (45, 64). ERV3 is a member of
an ERV family with more than 40 members, but only ERV3 has
intact ORF for viral proteins (65). The chromosomal location of
human ERV3 is characterized by a high number of pseudogenes
(data not shown), and the complete ERV3 locus is present only in
Old World primates with the exception of gorillas (66). Surpris-
ingly, approximately 1% of Caucasians with normal phenotype
have mutations in ERV3 which interrupt the ORF of the ERV3
envelope (67). This observation suggests that the ERV3 encoded
envelope protein is not critically involved in the physiological func-
tion of this gene. Interestingly, read-through transcript between
ERV3 and the neighboring zinc finger protein 117 (ZNF117) have
been described (68). Lower expression of these transcripts has been
observed in patients with multiple sclerosis (69). The human zinc
finger proteins ZNF107, ZNF138, and ZNF92 have high homology
with ZNF117. Together with other zinc finger proteins these genes
form a cluster on human chromosome 7. The physiological func-
tion of ZNF117 has not been clarified, but it seems possible that
this gene contributes to the biological effects of ERV3.
Endogenous retrovirus reactivation might occur only in tran-
scriptionally active regions of the genome. In such cases, ERV
reactivation might be only an epiphenomenon of chromatin
opening and depends on the presence of adequate competence
factors allowing transcription of the ERV. In such a model one
would expect that several ERV loci are activated at the same time
point. Our results show no evidence for such a general activa-
tion of ERV loci in HL. However, our analysis includes only
well characterized ERV loci which are detectable by the used
microarrays. Reactivation of ERV associated alternative promoter
in the CSF1R gene seems to be involved in the pathophysiology
of HL (7). The identification of such alternative transcription
start sites by means of DNA exon microarray analysis requires
new bioinformatics tools which are currently being developed in
our lab.
The up-regulation of ERV3 under conditions of cell cycle
inhibition and/or terminal differentiation is not specific for
HL. Whether such up-regulation occurs only in transformed
hematopoietic cells or also in other cell types has to be deter-
mined. Up-regulation of ERV3 in HL cells occurred under condi-
tions which are characterized by increased apoptosis. CoCl2 can
induce apoptosis in hematopoietic and non-hematopoietic tumor
cells (70–73). Similarly, vorinostat and other histone deacety-
lase inhibitors induce apoptosis in HL cells (74–76). If ERV3 is
a tumor suppressor gene (as suggested by the choriocarcinoma
data discussed above), expression of ERV3 in HL cells and other
hematopoietic cells under pro-apoptotic and anti-proliferative
conditions might indicate a tumor suppressing activity of ERV3
also in these cell types. The elucidation of ERV3 activities in the
context of growth inhibition and apoptosis might help the identifi-
cation of new targets for the treatment of HL and other malignant
diseases.
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